Financial Data and Key Metrics Changes - The company achieved net sales of $175 million for the quarter, with organic sales up 2% compared to the previous year [10] - Adjusted diluted earnings per share were $0.17, and adjusted EBITDA was $17 million, with adjusted gross margins at 55.7% and SG&A as a percentage of revenue at 45.2% [10] - A non-cash impairment charge of $77 million was recorded in the pain management and recovery reporting unit due to goodwill assessment [10] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems segment grew 5% organically, reaffirming its number one position in internal feeding [12] - The short-term internal feeding portfolio experienced double-digit growth globally, driven by the U.S. CoreTrack offering [13] - The pain management and recovery segment saw normalized organic sales up 3.4%, with the radiofrequency ablation (RFA) business growing nearly 14% [14][15] Market Data and Key Metrics Changes - The neonatal solutions business grew over 12% compared to the prior year [13] - The hyaluronic acid injections and intravenous infusion product lines reported a decline of over 20% due to pricing pressure [18] Company Strategy and Development Direction - The company closed the sale of its hyaluronic acid product line, focusing on growth in Specialty Nutrition Systems and Pain Management and Recovery segments [9] - The management is optimistic about improving commercial effectiveness through organizational enhancements and strategic partnerships [8] - The company aims to exit from China-sourced NeoMed products by 2026 as part of its supply chain strategy [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2025 financial guidance despite challenges from tariffs and market conditions [10][22] - The company anticipates approximately $15 million in incremental tariff-related manufacturing costs for the year [21] - Management noted that currency conditions have improved, and strategic segment growth remains healthy [22] Other Important Information - The company maintains a strong balance sheet with $90 million in cash and $105 million in debt as of June 30 [18] - Free cash flow for the quarter was negative approximately $4 million, but the company anticipates generating about $40 million of free cash flow for the year [19] Q&A Session Summary Question: 2025 guidance and its implications for SNS and pain management - Management reaffirmed full-year guidance, noting strong performance in Specialty Nutrition Systems and Pain Management segments [26][27] Question: Growth sustainability in the RF ablation business - Management highlighted strong momentum in the RF ablation segment, driven by a dedicated focus and a three-tiered offering [30][31] Question: Long-term impact of divestiture on income statement - Management indicated that the divestiture would not have a material impact on the bottom line, as strong performance in strategic segments would offset any losses [39][40]